[Inhibitor of plasminogen activator 1 (PAI-1) in hepatocellular carcinoma]
1Liver Cancer Institute, Zhongshan Hospital, Shanghai Medical University, Shanghai 200032.
Objective:
To study the expression of the type-1 inhibitor of plasminogen activator (PAI-1) on protein and mRNA in hepatocellular carcinoma (HCC), and the relation between PAI-1 and biological behaviour of HCC.
Method:
The tumor specimens of HCC (n = 48) and benign liver tumor (contorl n = 12) were tested by immunohistochemistry for the expression of PAI-1 protein. The tumor specimens of HCC (n = 20) and normal liver tissue (contorl n = 5) were evaluated by Northern blot analysis for the expression of PAI-1 mRNA.
Result:
PAI-1 protein and PAI-1 mRNA were higher in tumor cell than in the marginal tissue of tumor and in control (P < 0.01 and P < 0.05). In deaths 2 years after surgery, PAI-1 was increased as compared to the survival group (P < 0.05). When negative PAI-1 conupared with positive urokinase-type plasminogen activator (uPA) and positive uPA receptor (uPAR). The nambeigs invasion case increased, the difference was more significant than that in the group with negative PAI-1, uPA and uPAR (P = 0.039).
Conclusion:
The expression of PAI-1 protein and PAI-1 mRNA is increased in HCC. PAI-1 contributes to the invasion, metastasis and prognosis of HCC.